Epigenetic therapies – have they come of age?
The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies
Liquid biopsy moving to early cancer detection: is it still early times?
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
Pathogenic variants in HRR genes can be a risk factor for anthracycline-induced cardiotoxicity
A study presented at ESMO Congress 2022 highlights the need to identify predictors of anticancer drug toxicity as more complex treatments become available
Are we getting closer to apply AI-based techniques in clinical practice?
AI technology is being tested across tumour types and with different purposes, with an emerging trend for adding value to whole slide image analyses for HER2 status
AI and machine learning may change the course of translational research
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
Cancer Research
Food for thought: dietary effects on tumour metabolism and progression
Thanks to our deeper understanding of the underlying biology and molecular mechanisms that govern cancer, we are gaining important ground in tackling the myriad mediators of this disease.
New immunotherapies are explored to improve the treatment of solid tumours
From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed
Trials in precision oncology: current snapshot and future innovations
Increased use of molecular profiling is progressively improving decision-making processes in oncology compared with 20 years ago and helping to shape tomorrow’s clinical trials in targeted therapies
Liquid biopsy: novel approaches for early detection of cancer
Multi-omics approaches incorporating cell-free DNA and circulating tumour DNA show potential in early cancer detection and could help personalise treatment by tumour characteristics
Novel liquid biomarkers show promise in predicting clinical outcomes with immunotherapy
Although encouraging results are presented, standardisation of methodology and large-scale clinical trials are needed before potential candidates can be used in routine clinical practice